Bayer to acquire AT-01 & AT-05, investigational molecular imaging agents for the diagnosis of cardiac amyloidosis from Attralus: Berlin, Germany Wednesday, January 14, 2026, 11:00 ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...

Let’s Innovate Together!’ During my tenure as ASNC president, I will work tirelessly so we can innovate together as the ...

New data has revealed the continuing financial impact of radiology errors across the NHS, with diagnostic mistakes costing ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

LNTH READ THE FULL LNTH RESEARCH REPORT As 2026 begins, we are updating investors on Lantheus Holdings, Inc. (NASDAQ:LNTH), ...

The 4,700-square-meter facility at Tel Hashomer will include an on-site cyclotron and advanced imaging and targeted-treatment units, the medical center said.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...

SHINE announced today that it has completed its acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and its portfolio of diagnostic ...

About SHINE Technologies, LLC Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...